BeyondSpring: Up as drug for chemo-induced condition gets priority review tag

Beyondspring

01/06/2021 17:10

** Shares of drug developer  BYSI.O  rise 11.4% to $11.56 in
morning trade 
    ** Announces U.S. FDA acceptance and priority review of new
drug application for plinabulin and G-CSF combination 
    ** Combination to prevent chemotherapy-induced neutropenia
(CIN) - a condition which causes an abnormally low count of a
type of white blood cells
    ** FDA sets prescription drug user fee act (PDUFA) date for
Nov. 30 
    ** "If approved, plinabulin and G-CSF combination would be
an important new and improved option to prevent CIN for
approximately 467,500 cancer patients in the U.S. annually" -
CEO 
    ** Stock down 5% YTD 

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))